Wafaa El-Sadr

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8969632/publications.pdf

Version: 2024-02-01

156 papers	8,561 citations	81900 39 h-index	48315 88 g-index
164 all docs	164 docs citations	164 times ranked	9435 citing authors

#	Article	IF	Citations
1	Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. New England Journal of Medicine, 2007, 356, 1723-1735.	27.0	1,393
2	Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet, The, 2008, 371, 1417-1426.	13.7	809
3	Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet, The, 2014, 384, 241-248.	13.7	767
4	Integration of Antiretroviral Therapy with Tuberculosis Treatment. New England Journal of Medicine, 2011, 365, 1492-1501.	27.0	451
5	Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 491-501.	2.8	309
6	Africa in the Path of Covid-19. New England Journal of Medicine, 2020, 383, e11.	27.0	182
7	Impact of Antiretroviral Therapy on Incidence of Pregnancy among HIV-Infected Women in Sub-Saharan Africa: A Cohort Study. PLoS Medicine, 2010, 7, e1000229.	8.4	177
8	Why reinvent the wheel? Leveraging the lessons of HIV scale-up to confront non-communicable diseases. Global Public Health, 2011, 6, 247-256.	2.0	155
9	Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. Lancet HIV,the, 2018, 5, e291-e300.	4.7	155
10	Discontinuation of Prophylaxis againstMycobacterium aviumComplex Disease in HIV-Infected Patients Who Have a Response to Antiretroviral Therapy. New England Journal of Medicine, 2000, 342, 1085-1092.	27.0	146
11	Improving pathology and laboratory medicine in low-income and middle-income countries: roadmap to solutions. Lancet, The, 2018, 391, 1939-1952.	13.7	143
12	AIDS in America â€" Forgotten but Not Gone. New England Journal of Medicine, 2010, 362, 967-970.	27.0	140
13	Antiretroviral Treatment and Prevention of Peripartum and Postnatal HIV Transmission in West Africa: Evaluation of a Two-Tiered Approach. PLoS Medicine, 2007, 4, e257.	8.4	118
14	Financial Incentives for Linkage to Care and Viral Suppression Among HIV-Positive Patients. JAMA Internal Medicine, 2017, 177, 1083.	5.1	105
15	Predictors of Hypertension and Changes of Blood Pressure in HIV-Infected Patients. Antiviral Therapy, 2005, 10, 811-823.	1.0	103
16	The HIV care continuum. Aids, 2012, 26, 1735-1738.	2.2	101
17	Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. BMC Medicine, 2016, 14, 61.	5.5	100
18	A universal testing and treatment intervention to improve HIV control: One-year results from intervention communities in Zambia in the HPTN 071 (PopART) cluster-randomised trial. PLoS Medicine, 2017, 14, e1002292.	8.4	95

#	Article	IF	Citations
19	Scale-up of HIV Treatment Through PEPFAR. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, S96-S104.	2.1	92
20	The Problem of Late ART Initiation in Sub-Saharan Africa: A Transient Aspect of Scale-up or a Long-term Phenomenon?. Journal of Health Care for the Poor and Underserved, 2013, 24, 359-383.	0.8	91
21	A Review of Efficacy Studies of 6-Month Short-Course Therapy for Tuberculosis among Patients Infected with Human Immunodeficiency Virus: Differences in Study Outcomes. Clinical Infectious Diseases, 2001, 32, 623-632.	5.8	83
22	A Paradigm Shift: Focus on the HIV Prevention Continuum. Clinical Infectious Diseases, 2014, 59, S12-S15.	5.8	80
23	Swaziland HIV Incidence Measurement Survey (SHIMS): a prospective national cohort study. Lancet HIV,the, 2017, 4, e83-e92.	4.7	78
24	Limited awareness of pre-exposure prophylaxis among black men who have sex with men and transgender women in NewÂYork city. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 9-17.	1.2	76
25	Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. Aids, 2006, 20, 1109-1116.	2.2	69
26	Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. Nature Communications, 2021, 12, 4450.	12.8	67
27	Focus on Women: Linking HIV Care and Treatment with Reproductive Health Services in the MTCT-Plus Initiative. Reproductive Health Matters, 2005, 13, 136-146.	1.2	66
28	HIV Population Surveys â€" Bringing Precision to the Global Response. New England Journal of Medicine, 2018, 378, 1859-1861.	27.0	64
29	Prevention of mother-to-child transmission services as a gateway to family-based human immunodeficiency virus care and treatment in resource-limited settings: rationale and international experiences. American Journal of Obstetrics and Gynecology, 2007, 197, S101-S106.	1.3	63
30	HIV, Tuberculosis, and Noncommunicable Diseases. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, S87-S95.	2.1	63
31	Scale-up of HIV care and treatment: can it transform healthcare services in resource-limited settings?. Aids, 2007, 21, S65-S70.	2.2	62
32	Effectiveness of a combination strategy for linkage and retention in adult HIV care in Swaziland: The Link4Health cluster randomized trial. PLoS Medicine, 2017, 14, e1002420.	8.4	59
33	Host country responses to non-communicable diseases amongst Syrian refugees: a review. Conflict and Health, 2019, 13, 8.	2.7	59
34	HIV-Associated Tuberculosis: Diagnostic and Treatment Challenges. Seminars in Respiratory and Critical Care Medicine, 2008, 29, 525-531.	2.1	58
35	Factors associated with initiation of antiretroviral therapy in the advanced stages of HIV infection in six Ethiopian HIV clinics, 2012 to 2013. Journal of the International AIDS Society, 2016, 19, 20637.	3.0	48
36	Pregnant and breastfeeding women: A priority population for HIV viral load monitoring. PLoS Medicine, 2017, 14, e1002375.	8.4	44

#	Article	IF	Citations
37	The Impact of HIV Scale-Up on Health Systems: A Priority Research Agenda. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, S6-S11.	2.1	43
38	CD4+ Cell Count Testing More Effective Than HIV Disease Clinical Staging in Identifying Pregnant and Postpartum Women Eligible for Antiretroviral Therapy in Resource-Limited Settings. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 404-410.	2.1	43
39	Anxiety and depressive symptoms are associated with poor sleep health during a period of COVID-19-induced nationwide lockdown: a cross-sectional analysis of adults in Jordan. BMJ Open, 2020, 10, e041995.	1.9	41
40	Addressing Research Priorities for Prevention of HIV Infection in the United States. Clinical Infectious Diseases, 2010, 50, S149-S155.	5.8	40
41	Game Changers: Why Did the Scale-Up of HIV Treatment Work Despite Weak Health Systems?. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, S61-S63.	2.1	40
42	Characteristics and Outcomes among Older HIV-Positive Adults Enrolled in HIV Programs in Four Sub-Saharan African Countries. PLoS ONE, 2014, 9, e103864.	2.5	40
43	COVID-19 testing, case, and death rates and spatial socio-demographics in New York City: An ecological analysis as of June 2020. Health and Place, 2021, 68, 102539.	3.3	40
44	The President's Emergency Plan for AIDS Relief â€" Is the Emergency Over?. New England Journal of Medicine, 2008, 359, 553-555.	27.0	38
45	Use of a Comprehensive HIV Care Cascade for Evaluating HIV Program Performance. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, e44-e51.	2.1	38
46	Body Mass Index and the Risk of Serious Non-AIDS Events and All-Cause Mortality in Treated HIV-Positive Individuals: D:A:D Cohort Analysis. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 579-588.	2.1	38
47	Integrating HIV services and other health services: AÂsystematic review and meta-analysis. PLoS Medicine, 2021, 18, e1003836.	8.4	38
48	Building on the HIV chronic care platform to address noncommunicable diseases in sub-Saharan Africa. Aids, 2018, 32, S107-S113.	2.2	37
49	Keeping health facilities safe: one way of strengthening the interaction between disease-specific programmes and health systems. Tropical Medicine and International Health, 2010, 15, 1407-1412.	2.3	36
50	How Can the Health System Retain Women in HIV Treatment for a Lifetime? A Discrete Choice Experiment in Ethiopia and Mozambique. PLoS ONE, 2016, 11, e0160764.	2.5	36
51	Modeling the impact on the HIV epidemic of treating discordant couples with antiretrovirals to prevent transmission. Aids, 2011, 25, 2295-2299.	2.2	35
52	Reaching global HIV/AIDS goals: What got us here, won't get us there. PLoS Medicine, 2017, 14, e1002421.	8.4	35
53	Building on the HIV platform. Aids, 2018, 32, S1-S3.	2.2	34
54	Antiretroviral Therapy for Prevention Is a Combination Strategy. Current HIV/AIDS Reports, 2013, 10, 152-158.	3.1	32

#	Article	IF	Citations
55	Oral candidiasis in HIV infection: predictive value and comparison of findings in injecting drug users and homosexual men. Journal of Oral Pathology and Medicine, 1997, 26, 237-243.	2.7	31
56	Reproductive decisions in HIV-infected individuals. Lancet, The, 2005, 366, 698-700.	13.7	31
57	Design of the HPTN 065 (TLC-Plus) study: A study to evaluate the feasibility of an enhanced test, link-to-care, plus treat approach for HIV prevention in the United States. Clinical Trials, 2017, 14, 322-332.	1.6	31
58	Selecting a viral load threshold for routine monitoring in resourceâ€limited settings: optimizing individual health and population impact. Journal of the International AIDS Society, 2017, 20, e25007.	3.0	31
59	Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study. Journal of the International AIDS Society, 2014, 17, 19512.	3.0	29
60	Initiation of antiretroviral therapy among pregnant women in resource-limited countries: CD4+ cell count response and program retention. Aids, 2010, 24, 515-524.	2.2	27
61	PEPFAR Programs Linked To More Deliveries In Health Facilities By African Women Who Are Not Infected with HIV. Health Affairs, 2012, 31, 1478-1488.	5.2	27
62	Chinaâ€™s health assistance to Africa: opportunism or altruism?. Globalization and Health, 2016, 12, 83.	4.9	27
63	Population health and individualized care in the global AIDS response. Aids, 2016, 30, 2145-2148.	2.2	27
64	Letting HIV Transform Academia â€" Embracing Implementation Science. New England Journal of Medicine, 2014, 370, 1679-1681.	27.0	24
65	Identifying Perceived Barriers along the HIV Care Continuum. Journal of the International Association of Providers of AIDS Care, 2016, 15, 291-300.	1.5	24
66	Antiretroviral Therapy: A Promising HIV Prevention Strategy?. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, S116-S121.	2.1	23
67	Missed Opportunities to Address Cardiovascular Disease Risk Factors amongst Adults Attending an Urban HIV Clinic in South Africa. PLoS ONE, 2015, 10, e0140298.	2.5	23
68	Understanding low sensitivity of communityâ€based HIV rapid testing: experiences from the HPTN 071 (PopART) trial in Zambia and South Africa. Journal of the International AIDS Society, 2017, 20, 21780.	3.0	23
69	Ending AIDS as a public health threat by 2030: Time to reset targets for 2025. PLoS Medicine, 2021, 18, e1003649.	8.4	23
70	Addressing chronic diseases in protracted emergencies: Lessons from HIV for a new health imperative. Global Public Health, 2018, 13, 227-233.	2.0	22
71	Can the Success of HIV Scale-Up Advance the Global Chronic NCD Agenda?. Global Heart, 2016, 11, 403.	2.3	22
72	Clinician Practices and Attitudes Regarding Early Antiretroviral Therapy in the United States. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, e65-e69.	2.1	21

#	Article	IF	Citations
73	Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virusâ€"infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. Clinical Infectious Diseases, 2019, 68, 650-657.	5.8	21
74	Life in the Balance: Young Female Sex Workers in Kenya Weigh the Risks of COVID-19 and HIV. AIDS and Behavior, 2021, 25, 1323-1330.	2.7	20
75	The Effect of Methadone on Immunological Parameters among HIV-Positive and HIV-Negative Drug Users. American Journal of Drug and Alcohol Abuse, 1994, 20, 317-329.	2.1	19
76	The Link4Health study to evaluate the effectiveness of a combination intervention strategy for linkage to and retention in HIV care in Swaziland: protocol for a cluster randomized trial. Implementation Science, 2015, 10, 101.	6.9	19
77	Costs of Expanded Rapid HIV Testing in Four Emergency Departments. Public Health Reports, 2016, 131, 71-81.	2.5	19
78	Integrating cardiovascular disease risk factor screening into HIV services in Swaziland. Aids, 2018, 32, S43-S46.	2.2	18
79	Safer sex strategies for women: The hierarchical model in methadone treatment clinics. Journal of Urban Health, 1999, 76, 62-72.	3.6	17
80	Gender differences in HIV-positive persons in use of cardiovascular disease-related interventions: D:A:D study. Journal of the International AIDS Society, 2014, 17, 19516.	3.0	17
81	Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study. PLoS Medicine, 2017, 14, e1002424.	8.4	17
82	Covid-19, Ebola, and HIV â€" Leveraging Lessons to Maximize Impact. New England Journal of Medicine, 2020, 383, e106.	27.0	17
83	Effects of the Coronavirus Disease 2019 Pandemic on Human Immunodeficiency Virus Services: Findings from 11 Sub-Saharan African Countries. Clinical Infectious Diseases, 2022, 75, e1046-e1053.	5.8	17
84	Uptake of needle and syringe program services in the Kyrgyz Republic: Key barriers and facilitators. Drug and Alcohol Dependence, 2017, 179, 180-186.	3.2	16
85	Family Matters. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, S243-S249.	2.1	15
86	A pragmatic approach to monitor and evaluate implementation and impact of differentiated <scp>ART</scp> delivery for global and national stakeholders. Journal of the International AIDS Society, 2018, 21, e25080.	3.0	15
87	Abacavir use and risk of recurrent myocardial infarction. Aids, 2018, 32, 79-88.	2.2	15
88	Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study. EClinicalMedicine, 2019, 13, 91-100.	7.1	15
89	Contact Tracing: Barriers and Facilitators. American Journal of Public Health, 2022, 112, 1025-1033.	2.7	15
90	Gender Differences and Psychosocial Factors Associated with Quality of Life Among ART Initiators in Oromia, Ethiopia. AIDS and Behavior, 2016, 20, 1682-1691.	2.7	14

#	Article	IF	Citations
91	â€œTesting, Testingâ€: Multiple HIV-Positive Tests among Patients Initiating Antiretroviral Therapy in Ethiopia. Journal of the International Association of Providers of AIDS Care, 2017, 16, 546-554.	1.5	14
92	Clinical decision tools are needed to identify HIV-positive patients at high risk for poor outcomes after initiation of antiretroviral therapy. PLoS Medicine, 2017, 14, e1002278.	8.4	14
93	Risk for Nonâ€“AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy. Annals of Internal Medicine, 2021, 174, 768-776.	3.9	14
94	Willingness to use short-term oral pre-exposure prophylaxis (PrEP) by migrant miners and female partners of migrant miners in Mozambique. Culture, Health and Sexuality, 2017, 19, 1389-1403.	1.8	13
95	Expanding access to antiretroviral therapy through the public sector--the challenge of retaining patients in long-term primary care. South African Medical Journal, 2004, 94, 273-4.	0.6	13
96	Public Health Implications of Adapting HIV Pre-exposure Prophylaxis Programs for Virtual Service Delivery in the Context of the COVID-19 Pandemic: Systematic Review. JMIR Public Health and Surveillance, 2022, 8, e37479.	2.6	13
97	Transitioning to Country Ownership of HIV Programs in Rwanda. PLoS Medicine, 2016, 13, e1002075.	8.4	12
98	HIV Care and Treatment Beliefs among Patients Initiating Antiretroviral Treatment (ART) in Oromia, Ethiopia. AIDS and Behavior, 2016, 20, 998-1008.	2.7	12
99	Association Between HIV Programs and Quality of Maternal Health Inputs and Processes in Kenya. American Journal of Public Health, 2015, 105, S207-S210.	2.7	11
100	Persons living with <scp>HIV</scp> with advanced <scp>HIV</scp> disease: need for novel care models. Journal of the International AIDS Society, 2018, 21, e25210.	3.0	11
101	Optimizing HIV prevention and treatment outcomes for persons with substance use in Central Asia. Current Opinion in HIV and AIDS, 2019, 14, 374-380.	3.8	11
102	Health Systems Exist for Real People. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, S1-S2.	2.1	10
103	From START to finish: implications of the START study. Lancet Infectious Diseases, The, 2016, 16, 13-14.	9.1	10
104	Advanced Human Immunodeficiency Virus Disease at Diagnosis in Mozambique and Swaziland. Open Forum Infectious Diseases, 2017, 4, ofx156.	0.9	10
105	Gender differences in the use of cardiovascular interventions in <scp>HIV</scp>â€positive persons; the D:A:D Study. Journal of the International AIDS Society, 2018, 21, e25083.	3.0	10
106	Challenges and Opportunities in Chinaâ€™s Health Aid to Africa: Findings from Qualitative Interviews in Tanzania and Malawi. Globalization and Health, 2020, 16, 71.	4.9	10
107	Provider attitudes about childhood tuberculosis prevention in Lesotho: a qualitative study. BMC Health Services Research, 2020, 20, 461.	2.2	10
108	End of AIDSâ€”Hype versus hope. Science, 2014, 345, 166-166.	12.6	9

#	Article	IF	Citations
109	Innovation to confront Ebola in Sierra Leone: the community-care-centre model. The Lancet Global Health, 2015, 3, e361-e362.	6.3	9
110	A Randomized-Controlled Trial of Computer-based Prevention Counseling for HIV-Positive Persons (HPTN 065). Journal of AIDS & Clinical Research, 2017, 08, .	0.5	9
111	A timeâ€motion study of cardiovascular disease risk factor screening integrated into <scp>HIV</scp> clinic visits in Swaziland. Journal of the International AIDS Society, 2018, 21, e25099.	3.0	9
112	What one pandemic can teach us in facing another. Aids, 2020, 34, 1757-1759.	2.2	9
113	Expansion and scale-up of HIV care and treatment services in four countries over ten years. PLoS ONE, 2020, 15, e0231667.	2.5	9
114	HIV incidence, viremia, and the national response in Eswatini: Two sequential population-based surveys. PLoS ONE, 2021, 16, e0260892.	2.5	9
115	Post-vaccination outcomes in association with four COVID-19 vaccines in the Kingdom of Bahrain. Scientific Reports, 2022, 12, .	3.3	9
116	COVID-19 Vaccine Uptake and Factors Associated With Being Unvaccinated Among Lesbian, Gay, Bisexual, Transgender, Queer, and Other Sexual Identities (LGBTQ+) New Yorkers. Open Forum Infectious Diseases, 2022, 9, .	0.9	9
117	Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. Journal of Infectious Diseases, 2019, 220, 1629-1634.	4.0	8
118	Examining stigma, social support, and gender differences in unsuppressed HIV viral load among participants in HPTN 065. Journal of Behavioral Medicine, 2021, 44, 159-171.	2.1	8
119	Assessing the Information-Motivation-Behavioral Skills Model to Predict Pre-exposure Prophylaxis Adherence Among Black Men Who have Sex with Men and Transgender Women in a Community Setting in New York City. AIDS and Behavior, 2022, 26, 2494-2502.	2.7	8
120	HIV Treatment-As-Prevention Research: Taking the Right Road at the Crossroads. PLoS Medicine, 2015, 12, e1001800.	8.4	7
121	The PREVENT study to evaluate the effectiveness and acceptability of a community-based intervention to prevent childhood tuberculosis in Lesotho: study protocol for a cluster randomized controlled trial. Trials, 2017, 18, 552.	1.6	7
122	Itâ€™s all in the timing: Acceptability of a financial incentive intervention for linkage to HIV care in the HPTN 065 (TLC-Plus) study. PLoS ONE, 2018, 13, e0191638.	2.5	7
123	Improving child tuberculosis contact identification and screening in Lesotho: Results from a mixed-methods cluster-randomized implementation science study. PLoS ONE, 2021, 16, e0248516.	2.5	7
124	â€œWhat will we do if we get infected?â€• An interview-based study of the COVID-19 pandemic and its effects on the health and safety of sex workers in the United States. SSM Qualitative Research in Health, 2022, 2, 100027.	1.5	7
125	Cost-effectiveness of a combination strategy to enhance the HIV care continuum in Swaziland: Link4Health. PLoS ONE, 2018, 13, e0204245.	2.5	6
126	Changes in D-dimer after initiation of antiretroviral therapy in adults living with HIV in Kenya. BMC Infectious Diseases, 2020, 20, 508.	2.9	6

#	Article	IF	Citations
127	The Impact of Immunosuppression on Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: The D:A:D Study. Journal of Infectious Diseases, 2021, 223, 632-637.	4.0	6
128	The HIV Epidemic in the United States: A Time for Action. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, S63.	2.1	5
129	Maternal and Infant Outcomes With Concurrent Treatment of Tuberculosis and HIV Infection in Pregnant Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, e63-e66.	2.1	5
130	Changing Clinician Practices and Attitudes Regarding the Use of Antiretroviral Therapy for HIV Treatment and Prevention. Journal of the International Association of Providers of AIDS Care, 2017, 16, 81-90.	1.5	5
131	Costâ€effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States. Journal of the International AIDS Society, 2021, 24, e25690.	3.0	5
132	Bringing HIV services to key populations and their communities in Tanzania: from pilot to scale. Journal of the International AIDS Society, 2021, 24, e25718.	3.0	5
133	Association of sociodemographic factors with needle sharing and number of sex partners among people who inject drugs in Egypt. Global Public Health, 2022, 17, 1689-1698.	2.0	5
134	Bridging the Divide. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, S59-S60.	2.1	4
135	Getting the balance right: Scaling-up treatment and prevention. Global Public Health, 2017, 12, 483-497.	2.0	4
136	Factors Associated with Use of Short-Term Pre-Exposure Prophylaxis for HIV Among Female Partners of Migrant Miners in Mozambique. AIDS Patient Care and STDs, 2017, 31, 528-534.	2.5	4
137	Exploring individual-level barriers to HIV medication adherence among men who have sex with men in the HIV Prevention Trials Network (HPTN 065) study. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 33, 1-10.	1.2	4
138	How can progress towards Ending the HIV Epidemic in the United States be monitored?. Clinical Infectious Diseases, 2021, , .	5.8	4
139	Lessons From Harlem: Relevance to a Global Epidemic. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, S24-S26.	2.1	3
140	Putting quality at the heart of HIV programs. Aids, 2015, 29, S119-S120.	2.2	3
141	Beyond the Magic Bullet: What Will It Take to End the AIDS Epidemic?. American Journal of Public Health, 2021, 111, 1234-1236.	2.7	3
142	The Looming Threat: Cancer in Sub-Saharan Africa. Oncologist, 2021, 26, e2099-e2101.	3.7	3
143	Effect of COVID-19 Pandemic on Older New York City Residents Living at Home. Journal of Community Health, 2022, 47, 361-370.	3.8	3
144	Difference in clinical implications of CD4 counts among HIV-infected homosexual men and injection drug using men and women. Statistics in Medicine, 1995, 14, 1889-1900.	1.6	2

#	Article	IF	Citations
145	Ebola: the real lessons from HIV scale-up. Lancet Infectious Diseases, The, 2015, 15, 506.	9.1	2
146	Is Omicron Showing Us the Path Ahead?. American Journal of Public Health, 2022, , e1-e2.	2.7	2
147	When to Start ART in Africa. New England Journal of Medicine, 2013, 368, 2238-2238.	27.0	1
148	Geographic Utilization of Gift Cards Used for Financial Incentives to Encourage Viral Suppression: Findings from HPTN 065. AIDS Research and Human Retroviruses, 2014, 30, A287-A287.	1.1	1
149	The Impact of Implementing a Financial Incentive Program for Viral Suppression on the Clinic Environment: A Qualitative Substudy of HPTN 065. AIDS Research and Human Retroviruses, 2014, 30, A104-A105.	1.1	1
150	The HIV response and global health. Lancet, The, 2019, 393, 1696.	13.7	1
151	No Need for Apologies. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, S68-S71.	2.1	0
152	A Chronicle of Hope and Promise. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, S49-S50.	2.1	0
153	Clinical trials provide the evidence critical for patient empowerment. Journal of the International AIDS Society, 2013, 16, 18811.	3.0	0
154	Understanding of Viral Load among Participants Receiving Financial Incentives for ART Adherence: Findings from a Qualitative Substudy of HPTN 065. AIDS Research and Human Retroviruses, 2014, 30, A105-A105.	1.1	0
155	Early initiation of antiretroviral therapy: debate over? â€“ Authors' reply. Lancet Infectious Diseases, The, 2016, 16, 769-770.	9.1	0
156	Consumption Rate of a Wholeâ€Food Macronutient Supplement for Adults Initiating Antiretroviral Therapy in Kenya. FASEB Journal, 2013, 27, 619.7.	0.5	0